Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of IY-828026 in Healthy Adult Volunteers
NCT07433556Phase 1Recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IY-828026 in gastroesophageal reflux disease (GERD) (10 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events at Day 15, Maximum Plasma Concentration and 11 more. Started Mar 2026; status: recruiting.
02
Drugs
IY-828026
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07433556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07433556.